Using up-front, broadpanel genomic tests that include hundreds of genes can save money and, in some cases, improve outcomes compared with other diagnostic approaches, especially in lung cancer but also increasingly in breast, colorectal, skin, and other cancers.
Cell-free DNA-based detection of microsatellite instability status was found to be highly concordant with tissue-based MSI testing.
Although research findings have established many applications for genetic information in breast cancer, not enough patients are being tested for the risk of germline mutations and new strategies are needed to broaden the clinical application of genomic advancements.
Sometimes referred to as massively parallel sequencing, next-generation sequencing evaluates millions of DNA sequences simultaneously, representing a true revolution compared with traditional, labor-intensive methods in which far less DNA could be sequenced at once.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
Mohammad Razaq, MD, discusses how the detection of driver mutations has changed the way treatment is approached in advanced non–small cell lung cancer.
Alain Borczuk, MD, discusses the recent advancements in lung cancer treatment, the evolving field, and the future potential for liquid biopsies.
Mark E. Burkard, MD, PhD, discussed the significance of utilizing markers in the blood and highlighted emerging actionable mutations in breast cancer.
Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.
MAPK/ERK gene alterations, primarily receptor tyrosine kinases, BRAF, and CDK4/6 amplifications, were found to be present in more than half of patients with heavily pretreated metastatic prostate cancer.